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Abstract
Fatigue occurs frequently in patients with cancer, neurological diseases and chronic inflammatory diseases, but the
biological mechanisms that lead to and regulate fatigue are largely unknown. When the innate immune system is
activated, heat shock proteins (HSPs) are produced to protect cells. Some extracellular HSPs appear to recognize
cellular targets in the brain, and we hypothesize that fatigue may be generated by specific HSPs signalling through
neuronal or glial cells in the central nervous system. From a cohort of patients with primary Sjögren’s syndrome,
20 patients with high and 20 patients with low fatigue were selected. Fatigue was evaluated with a fatigue visual analogue
scale. Plasma concentrations of HSP32, HSP60, HSP72 and HSP90a were measured and analysed to determine if there
were associations with the level of fatigue. Plasma concentrations of HSP90a were significantly higher in patients with
high fatigue compared with those with low fatigue, and there was a tendency to higher concentrations of HSP72 in
patients with high fatigue compared with patients with low fatigue. There were no differences in concentrations of
HSP32 and HSP60 between the high- and low-fatigue groups. Thus, extracellular HSPs, particularly HSP90a, may signal
fatigue in chronic inflammation. This supports the hypothesis that fatigue is generated by cellular defence mechanisms.
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Introduction
Fatigue has been described as ‘an overwhelming sense
of tiredness, lack of energy and feeling of exhaustion’.1
It is a frequent feature of chronic inflammatory and
immunological diseases, cancer, and neurological dis-
orders. Patients often have fatigue so profound that it
severely interferes with activities of daily living and
leads to longstanding sick leave and disability, resulting
in economic burdens to society.
The mechanisms that lead to and regulate fatigue are
debated. Depression and socioeconomic burden are
important, but increasing evidence points to genetic
and molecular mechanisms that are activated during
inflammation and cellular stress conditions, and sig-
nalled via neuro-immune and oxidative/nitrosative
stress pathways.2–4
‘Sickness behaviour’ is a phenomenon observed in
animals during infection or ‘danger’, and it is highly
conserved during evolution.5 It is characterized by sleepi-
ness; depressive mood; social withdrawal; and loss of
grooming, thirst, and appetite. Sickness behaviour
constitutes a complex and automated behaviour thought
to protect the sick individual from predators. Fatigue in
humans has some similarities to sickness behaviour in
other animals. Several animal studies have explored the
pathways involved in sickness behaviour and demon-
strated the fundamental role of IL-1b signalling to the
brain.6 Activation of innate immunity cells such as
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macrophages and granulocytes rapidly leads to increased
production of IL-1b. This activates other immune cells
to destroy and eliminate the pathogen or the endogenous
danger molecules. Simultaneously, IL-1b is actively
transported to the brain through several mechanisms;
once in the brain, it binds to specific IL-1 receptors.7
This initiates the subconscious sickness behaviour,
which persists throughout the immune response.
In humans, studies indicate that IL-1b is important in
the generation of fatigue.8–10 In chronic inflammatory
diseases or other conditions characterized by cellular
stresses, IL-1b signalling is continuously active; thus,
the fatigue phenomenon is persistent and chronic.
Treatment with IL-1 blocking agents improves fatigue
in humans.9,10 This supports the hypothesis that IL-1b
plays a role in fatigue signalling in humans.
When the innate immune system is activated during
infections, pathogens are engulfed and destroyed by
highly reactive oxygen and nitrogen species (ROS and
RNS, respectively) in phagolysosomes. This is an
important part of the body’s first line of defence against
pathogens. High levels of ROS/RNS can be detrimen-
tal, as they can cause DNA damage and cell death.
To protect cellular life, cells have therefore developed
strong defence systems composed of a large number of
active substances and enzymes that counteract the
reactive molecules, maintain redox homeostasis and
protect vital cellular functions. Oxidative stress is a
term used to describe the situation in which reactive
molecules prevail over antioxidant and cellular
defences, such as in infectious or chronic inflammatory
conditions. Several studies have indicated an associ-
ation between oxidative stress and fatigue.11–15
Heat shock proteins (HSPs) are highly conserved
proteins that serve important protective functions
under conditions of oxidative stress and a wide range
of other cellular stresses. HSPs constitute a large family
of proteins and are classified according to their molecu-
lar mass.16 Some HSPs are known for their role in pro-
tein folding, where they serve as chaperone molecules.
Other HSPs are induced upon cellular stress and are
released from the cells. These extracellular HSPs take
part in cell-to-cell signalling; it is tempting to speculate
that extracellular HSPs are part of a signalling system
that coordinates several overarching defence mechan-
isms, including behavioural strategies for survival.
Because of the central role of HSPs in cellular defence
and the presence of cellular targets for some HSPs in
the brain,17,18 we hypothesize that certain HSPs play a
signalling role in fatigue.
Primary Sjögren’s syndrome (pSS) is a chronic auto-
immune disease that is characterized by inflammation of
exocrine glands and subsequent dryness phenomena.19
Fatigue is common in pSS patients, with a reported
prevalence of 30–67%, depending on the fatigue instru-
ments used and the patient cohorts investigated.20,21
It poses a major impact on quality of life, described
by patients as an ever-present state, unpredictable, fluc-
tuating, and beyond their own control.22 As observed in
other diseases, the severity of fatigue is influenced by
pain, depression and sleep disturbances.20,21
As there is no effective drug treatment for pSS, gene
activity and molecular interactions are relatively undis-
turbed by drug treatment compared with many other
diseases. Therefore, we chose to investigate the expres-
sion of HSPs in a cohort of patients with pSS. To
explore the potential role of HSPs in fatigue, we included
four different HSPs based on the following criteria: (1)
secretion from cells upon stimulation, (2) expression in
the brain and the presence of targets on cells in the brain,
and (3) previous reports of possible associations with
fatigue or fatigue-related mechanisms.
Patients and methods
From a cohort of 72 pSS patients, all of whom fulfilled
the American–European Consensus Group criteria for
pSS,23 we selected the 20 patients with the highest and
the 20 patients with the lowest scores on a fatigue visual
analogue scale (fVAS). The patients took part in a study
in which they were admitted to Stavanger University
Hospital for research purposes only. All examinations,
testing and blood sampling were performed under strict
standardized conditions, with blood sampling at fixed
times during the day.
fVAS is a generic fatigue instrument that has been
widely used to measure fatigue in patients with pSS and
other diseases.24 It consists of a 100-mm horizontal line
with vertical anchoring lines. The description at the left
end (0mm) is ‘no fatigue’, and the description at the
right end (100mm) is ‘fatigue as bad as it can be’. The
subjects are asked to draw a vertical line at the point
corresponding to their experience of fatigue the last
week, and the distance from the left anchor is mea-
sured, yielding a numerical score for fatigue.
The Beck Depression Inventory (BDI) was used to
assess mood. A BDI score of <13 is normally regarded
as no depression, a score of 13–19 represents mild
depression and a score of >19 reflects moderate-to-
severe depression.
Blood samples
Routine haematological and biochemical tests were per-
formed at the hospital’s routine laboratory. Antinuclear
antibodies and antibodies to SSA/Ro and SSB/La were
analysed with the QUANTA Lite ENA 6 kit (Inova
Diagnostics, San Diego, CA, USA). Positive results
were confirmed by QUANTA Lite SS-A and SS-B.
The clinical characteristics of the patients are provided
in Table 1.
Samples to be analysed for HSPs were collected in
EDTA tubes on ice, centrifuged at 2500 g at 4C for
15min, aliquoted and stored at 80C until analyses.
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Plasma concentrations of HSP32, HSP60, HSP72 and
HSP90a were measured with commercial ELISA kits
(Enzo Life Sciences, Farmingdale, NY, USA).
Samples were thawed on ice and diluted 1:3 (HSP32),
1:2 (HSP60), 1:4 (HSP72) and 1:20 (HSP90a) with
assay buffer. All samples were assayed in duplicate
and analysed according to the manufacturer’s recom-
mendations. HSP concentrations were read as absorb-
ance at 450 nm for HSP32, HSP60 and HSP90a, and
495 nm for HSP72 on a Synergy H1 plate reader
(BioTek, Bad Friedrichshall, Germany). Coefficients
of variation (CV) between duplicates were <15% for
HSP32 and HSP90a and <20% for HSP60 and HSP72.
Intra-assay variability (Enzo Life Sciences) was <10%
for the HSP32, HSP60 and HSP90 kits (n¼ 10). For the
HSP72 kit, intra-assay variability was <10% for high
concentrations (0.5 ng/ml) and 15% for low concentra-
tions (0.14 ng/ml) (n¼ 20).
Statistics
Owing to the non-normal distribution of the data,
results are presented as median and range and Mann–
Whitney U-test was used for comparisons of con-
tinuous variables in the two patient groups. Logistic
regression was used to analyse associations between
fatigue and HSP concentrations and other relevant
patient data. Relevant variables were first tested in a
univariable logistic regression model, and only
variables with a P-value< 0.2 were added to the multi-
variable logistic regression model. Stepwise backward
and forward model selection was used to choose the
final multivariable model. Goodness of fit was exam-
ined by the Hosmer–Lemeshow test. For all analyses,
significance was set to P< 0.05. SPSS 22 and RStudio
0.98.1102 (with R 3.1.2) were used for statistical ana-
lysis and generation of graphs.
Ethics approval and patients consent
The study was performed according to the Declaration
of Helsinki and approved by the Regional Ethics
Committee West (2010/1455). All participants signed
a legal consent form and were free to refuse any specific
part of the examination.
Results
Plasma concentrations of the four different HSPs in the
high- and low-fatigue groups are illustrated in Figure 1.
HSP90a plasma concentrations were considerably
higher in patients with high vs. low fatigue: 40.8
(20.0–105.0) vs. 29.9 (4.9–73.3) ng/ml (P¼ 0.02). For
HSP72 there was a tendency to higher concentration
in the high- vs. low-fatigue group, not reaching
statistical significance: 1.14 (0.32–12.32) vs. 0.32
Table 1. Selected clinical variables for patients with pSS with






Age, yr [range] 58 [32–79] 59 [36–87] 1.00
Duration, yr [range] 9.1 [0.8–14.8] 4.1 [1.8–11.0] 0.04
Female sex (%) 16 (80) 18 (90) 0.82
Anti-SSA/SSB (%) 18 (90) 14 (70) 0.31
CRP [mg/l), median
[range]
3 [0–13] 0 [0–8] <0.01
BDI scores, median
[range]
13 [5–38] 6 [0–18] <0.01
fVAS scores, median
[range]
88 [76–96] 20 [3–44] <0.01
Immunosupressive
drugs (%)
9 (45) 8 (40)
Corticosteroids (%) 2 (10) 0
Antimalarials (%) 5 (25) 3 (15)
Corticosteroids and
antimalarials (%)





SSA: Sjögren’s-syndrome-related antigen A (Ro); SSB: Sjögren’s-syn-























Figure 1. HSP plasma concentrations compared with levels of
fatigue. HSP90a concentration differed between high- and low-
fatigue groups (P¼ 0.02). The difference in HSP72 concentrations
between high- and low-fatigue groups was close to significant
(P¼ 0.06). There were no associations between fatigue level and
plasma concentrations for HSP32 and HSP60. For ease of pres-
entation, one data point for HSP60 (210 ng/ml) in a low-fatigue
patient was not included in the Figure.
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(0.32–15.41) ng/ml (P¼ 0.06). For HSP32 and HSP60,
there were no significant differences between the groups
with high and low fatigue: HSP32, 3.02 (0.67–8.25) vs.
3.08 (0.0–7.63) ng/ml (P¼ 0.48); HSP60, 3.0 (3.0–5.0)
vs. 3.0 (3.0–210.0) ng/ml (P¼ 0.25). Because of the
higher number of standards needed for HSP72 and
HSP90a analyses, one sample from each of these two
groups (n¼ 4) were excluded owing to the limited
number of wells on the plates. Twelve out of the 156
samples (7.7%) analysed had CVs that were too high
for duplicates and were thus excluded from analysis
(HSP72¼ 6; HSP60¼ 5; and HSP90a¼ 1).
To investigate whether relevant variables other than
HSP90a influenced the fVAS scores, a multivariable
logistic regression model was fitted, with high- and
low-fatigue groups as the dependent variable and
HSP90a, BDI, age, sex, disease duration, C-reactive
protein levels and the presence of anti-SSA/SSB Abs
as independent variables. In both backward and for-
ward selection, only HSP90a and BDI remained in
the final model (Table 2). The Hosmer–Lemeshow
test for goodness of fit demonstrated a good model fit
for the final model (P¼ 0.71).
To further investigate the influence of depression,
patients were dichotomized into one group with BDI
scores <13 and a second group with BDI scores 13.
Plasma concentrations of HSP32, HSP60, HSP72 and
HSP90a were then compared between these groups.
There were no differences in HSP concentrations
between the two BDI groups (Figure 2).
Discussion
We found that plasma levels of HSP90a were signifi-
cantly higher in pSS patients with high fatigue com-
pared with those with low fatigue. In addition, there
was a close to significant increase in HSP72 levels in
patients with high vs. low fatigue. The influence of
HSP90a was considerable, as the odds ratio for high
vs. low fatigue was 1.12, indicating that an increase
of 1 ng/ml in the HSP90a concentration increased
the odds of being in the high-fatigue group by 12%.
The influence of depression was even stronger than
for HSP90a, as a rise of 1 in the BDI score increased
the odds of being in the high-fatigue group by 55%. No
differences in HSP32 and HSP60 levels were observed
between the high- and low-fatigue groups.
The influence of depression on fatigue, as revealed in
the multivariate model, was expected. It is well known
that affective states can have a strong impact on fati-
gue.25,26 However, this association is a complex issue,
and it is important to realize that questionnaires used
for assessing fatigue and depression often have similar
wording. This may lead to circular reasoning and false
conclusions regarding their relationship. Moreover,
there are indications that depression and fatigue may
be signalled through more or less shared molecular
pathways via the IL-1 system.27,28 Of note in this
regard is the lack of difference in HSP90a concentra-
tions between the groups with and without depression.
This suggests that HSP90a itself has no direct effect on
the depressive state.
Our findings point to the possibility of a mechanism in
which extracellular HSP90a and, to a lesser degree,
HSP72 signal to the brain and induce a state of fatigue.
This implies that the HSPs have to cross the blood–brain
barrier (BBB). Recombinant HSP72 has been demon-
strated to cross the BBB in ischaemic brains.29 Whether
this is true for HSP90a is unknown, but it raises the
question of whether HSPs can be transported across
the BBB under normal conditions or only under certain
conditions, such as inflammation. Specialized areas of the
BBB, known as the circumventricular organs, have no
Table 2. Logistic regression model for association of HSP90a
and relevant variables with high and low fatigue.
Variables OR CI (95%) P-Value
HSP90a 1.12 1.02–1.24 0.02
BDI 1.55 1.09–2.21 0.02
Variables not in the final model: age, duration, sex, anti-SSA/SSB, and CRP.
OR: odds ratio; CI: confidence interval.
100 BDI score < 13




















Figure 2. HSP plasma concentrations vs. BDI score. Patients
were dichotomized into one group with no depression
(BDI< 13) and one group with mild-to-severe depression
(BDI 13). Plasma concentrations of HSP32, HSP60, HSP72 and
HSP90a were then compared between the two depression
groups. No differences in BDI score and plasma levels of the
respective HSPs were observed between the two groups. For
ease of presentation, one data point for HSP60 (210 ng/ml) in a
low-fatigue patient was not included in the figure.
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functional BBB because of fenestrated capillaries, and
they permit the passage of small molecules across the
BBB.30 The circumventricular organs could represent a
route for HSP trafficking and signalling into the brain.
Another possible transport option through the BBB
is via exosomes. Exosomes are nanovesicles that con-
tain RNA, microRNA and intracellular-derived pro-
teins. Exosomes participate in intercellular signalling
by being actively taken up and then releasing their con-
tents.31–33 Exosomes constitute a major secretory path-
way for HSPs and can cross the BBB.34–37
A third possibility is that HSP90a and HSP72
are influenced by a common factor that more dir-
ectly influences fatigue. If this is the case, levels of
HSP90a and HSP72 may simply vary in response to
this factor.
Finally, it could be that HSPs act as damage asso-
ciated molecular proteins (DAMPs) together with redox-
derived DAMPs on innate immunity cells by activating
their TLRs, thus inducing the fatigue phenomenon.38
Specific receptors for HSPs have not been identified in
neuronal or glial brain cells. However, TLR4, which is
known to be activated by bacterial surface LPS, is a
receptor expressed on both neurons and microglial
cells. Interestingly, with respect to fatigue, administration
of LPS to animals induces sickness behaviour, while sim-
ultaneous blocking of the TLR4 signalling pathway by
interfering peptides prevents the behaviour.39 In addition
to LPS, HSP90a and HSP72 are among the endogenous
molecules that activate TLR4.18,40
In cell cultures, HSP32, HSP72 and HSP90a activate
microglial cells via TLR4 and lead to cytokine produc-
tion by activation of p38 MAPK and NF-kB.41 In the
context of fatigue generation, it is therefore possible
that HSPs in humans interact with TLR4 on microglia
and produce IL-1, which is a known inducer of sickness
behaviour.6 Another possibility is a direct influence on
cerebral neurons through HSP interactions with TLR4
on the surface of the neurons. The presence of TLR4 on
cerebral neurons, with co-localization of HSP70, has
previously been demonstrated in vivo.42
We did not find any association between fatigue and
levels of HSP60 or HSP32. A recent study found anti-
bodies against epitopes of bacterial and human HSP60
in patients with myalgic encephalomyelitis;43 however,
to our knowledge, there are no reports regarding blood
levels of HSP60 protein and fatigue.
This study has some limitations. It could be argued
that we should have used other fatigue measuring
instruments, such as multidimensional or disease-speci-
fic instruments. However, more than 200 different fati-
gue instruments exist today, and it is difficult to argue
the superiority of one over the other. Because it is well
known that VAS show good responsiveness to change
over time, and owing to of our long-term experience
with the fVAS, we regarded this as the most optimal
choice for this study.
Also, it has previously been documented in pSS that a
number of other factors influence fatigue, such as muscu-
lar and joint pain, mental depression and poor sleep.20,21
The severity of fatigue in the individual patient is there-
fore a complex phenomenon, modulated by several cofac-
tors, and cannot be attributed to one single player.
In the HSP60 and HSP72 assays, some samples had
signals close to and under the lower limit of detection,
resulting in high variation between duplicate measures.
Five HSP60 samples and six HSP72 samples were con-
sequently removed from analyses. Serum might have
been a better sample matrix for HSP60 and HSP72,
but we choose to use plasma because we wanted to
employ rapid centrifugation and aliquoting of samples
at low temperature to avoid degradation of analytes.
Importantly, to be valid, our findings need to be repli-
cated in other and even larger cohorts of pSS patients,
and also in cohorts of patients with other diseases.
The strengths of our study are the relatively large
groups of well-characterized patients, who were matched
in age and nearly matched in sex and were not undergo-
ing drug treatment that could potentially interfere with
analysis.
In conclusion, extracellular HSP90a and, to a lesser
degree, HSP72 may represent a mechanism by which
fatigue is signalled to the brain under conditions char-
acterized by cellular stress, such as chronic inflamma-
tory diseases. These counteractive and down-regulatory
processes of inflammation may explain why the severity
of fatigue is seldom reported to be a function of disease
activity or inflammatory markers.
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